Prometheus Biosciences

63 articles about Prometheus Biosciences

• In Memoriam – Friend, Scientific Innovator, Advisor and Board Chair Dr. Tadataka Yamada Has Passed Away

  8/5/2021

  Prometheus Biosciences, Inc., with great sorrow announced that its Chairman of the Board, Tadataka Yamada, M.D., KBE, passed away unexpectedly on August 4, 2021.

• Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn’s Disease

  8/2/2021

  Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced the initiation of the APOLLO-CD Phase 2a clinical trial evaluating PRA023 for moderate-to-severe Crohn’s disease (CD), with first patient enrollment.  

• Prometheus Biosciences Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-to-Severe Ulcerative Colitis (UC)

  7/19/2021

  Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced the initiation of the Phase 2 ARTEMIS-UC clinical trial evaluating PRA023 for moderate-to-severe ulcerative colitis (UC), with first patient enrollment

• Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021Featuring management and expert-led discussions on the science of TL1A, including the application and clinical trial approach of PRA023 in Inflammatory Bowel Disease

  7/15/2021

  Prometheus Biosciences, Inc. today announced it will host its virtual R&D Day for analysts and investors at 9:00 a.m. ET on Wednesday, July 28, 2021.

• Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ Platform

  6/21/2021

  Prometheus Biosciences, Inc. today announced it has received a $10 million milestone payment from Dr. Falk Pharma GmbH under its collaboration agreement to develop and commercialize Prometheus’ second program, PR600.

• Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference

  5/25/2021

  Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD), today announced that Mark McKenna, President and CEO, and Laurens Kruidenier, CSO, will present at the Jefferies Virtual Healthcare Conference

• Fred Hassan, Former CEO of Schering-Plough and Former Chairman of Bausch & Lomb, Joins Prometheus Biosciences Board

  5/17/2021

  Prometheus Biosciences, Inc., a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease, announced the appointment of Fred Hassan to its Board of Directors.

• Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference

  5/14/2021

  Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, President and CEO, will participate virtually in a fireside chat during the 2021 RBC Capital Markets Global Healthcare Conference

• Prometheus Biosciences Reports First Quarter 2021 Financial Results and Provides a Corporate Update

  5/13/2021

  PRA023, an anti-TL1A mAb, on track to initiate Phase 2 study for Ulcerative Colitis and Phase 2a study for Crohn’s Disease in 3Q 2021

• Prometheus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

  3/16/2021

   Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the closing of its initial public offering

• 

  Longboard, Prometheus Hit the Market with Hopes of Raising Over $250 Million Combined

  3/12/2021

  The two pharmaceutical companies are going public and anticipate raising more than $250 million to advance research and development programs and support their business initiatives.

• Prometheus Biosciences Commences Dosing in Multiple Ascending Dose (MAD) Portion of Ongoing Phase 1a Clinical Study of PRA023

  3/3/2021

  - PRA023 is a TL1A antibody targeting both inflammation and fibrosis in patients with ulcerative colitis and Crohn's disease - - PRA023 is being developed to be used in combination with a companion diagnostic to identify responders in novel precision medicine approach -

• Prometheus Biosciences Announces Appointments of Judith L. Swain, MD and Helen C. Adams, CPA to its Board of Directors

  2/16/2021

  Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the appointments of Judith L. Swain , MD and Helen C Adams to its board of directors

• Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study

  12/15/2020

  - PRA023 is a TL1A antibody targeting both inflammation and fibrosis in patients with ulcerative colitis and Crohn's disease - - PRA023 is being developed to be used in combination with a companion diagnostic to identify responders in novel precision medicine approach -

• Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease

  11/9/2020

  Proceeds to accelerate clinical development of PRA023, a potential best in class TL1A antibody for IBD, and expansion of Promtheus' 360 platform

• Prometheus Biosciences Appoints Olivier Laurent, Ph.D. as Chief Technology Officer

  9/29/2020

   Prometheus Biosciences, Inc., ("Prometheus") a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of inflammatory bowel disease (IBD), announced today the appointment of Olivier Laurent, Ph.D. as Chief Technology Officer

• Prometheus Biosciences Launches Monitr™ COVID-19 Assistance Program (M.C.A.P.)

  3/23/2020

  Prometheus Biosciences, Inc., Inc. ("Prometheus"), a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases, announced today that it has launched the Monitr™ COVID-19 Assistance Program (M.C.A.P.) to provide adult Crohn's disease (CD) patients with access to this valuable test.

• Prometheus Biosciences, Inc., Enters Into Multi-Target Strategic Collaboration with Takeda to Develop Targeted Therapies for Inflammatory Bowel Disease

  10/3/2019

  Agreement Leverages Prometheus Biosciences' Proprietary Bioinformatics Analysis Platform, Companion Diagnostics to Speed Development and Discovery

• 

  Artificial Organs for Biopharma Research and More

  7/2/2018

  There has been recent coverage of 3D bioprinting and how it has the potential to create a brave new world of printed organs to be used in biopharma research and maybe someday to even be used in organ transplants.

• Prometheus BioScience Inc. Provides Update On Hepastem NASH-Fibrosis Program With Late-Breaking Preclinical Data At 2016 American Association for Study of Liver Diseases Meeting

  11/14/2016